In 314 patients with COPD, nebulised glycopyrronium/formoterol/budesonide twice daily was non-inferior to the same triple combination by MDI for change in trough FEV1 at 12 weeks (difference -0.00 L, 95% CI -0.04 to 0.04); adverse events were comparable.
RCTn = 314
Kodgule et al. Efficacy and safety of novel nebulized combination of glycopyrronium, formoterol and budesonide in comparison with metered dose inhaler of glycopyrronium, formoterol and budesonide in COPD - A randomized, double-blind, double-dummy clinical trial